Motley Fool Wealth Management LLC Decreases Holdings in Cellebrite DI Ltd. $CLBT

Motley Fool Wealth Management LLC trimmed its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 14.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 564,836 shares of the company’s stock after selling 92,647 shares during the period. Motley Fool Wealth Management LLC owned 0.24% of Cellebrite DI worth $10,184,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the business. CWM LLC lifted its holdings in Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after buying an additional 889 shares during the last quarter. SkyView Investment Advisors LLC lifted its holdings in Cellebrite DI by 2.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after buying an additional 970 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Cellebrite DI by 17.8% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,216 shares of the company’s stock worth $220,000 after buying an additional 1,850 shares during the last quarter. Seelaus Asset Management LLC lifted its holdings in Cellebrite DI by 11.9% during the 4th quarter. Seelaus Asset Management LLC now owns 18,850 shares of the company’s stock worth $340,000 after buying an additional 2,000 shares during the last quarter. Finally, Advisory Services Network LLC purchased a new stake in Cellebrite DI during the 3rd quarter worth about $40,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 13,269 shares of company stock valued at $169,592. 5.70% of the stock is currently owned by insiders.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $12.98 on Wednesday. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98. The company has a market capitalization of $3.24 billion, a P/E ratio of 46.36, a PEG ratio of 1.66 and a beta of 1.17. The stock has a 50-day simple moving average of $13.27 and a 200-day simple moving average of $15.12.

Analyst Ratings Changes

A number of analysts have issued reports on CLBT shares. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. DA Davidson started coverage on Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target for the company. Finally, Needham & Company LLC decreased their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.